May this year，The results of the first batch of national drug price negotiations were announced，Non -small cell lung cancer targeted drugs Ekntinib (Zhejiang Beidacorina) and Geffitinib (Irisha) and anti -hepatitis B virus drugs have completed the price reduction negotiation procedure for Norofovir ester。It is reported，In the next step, the price negotiation 18 drugs are basically still hot drugs in the tumor market。

 

  In the field of tumor treatment，With the listing of new drugs，Tabletic drugs and immunotherapy brings more hope to patients。Precision Medical era，Chemotherapy is still the cornerstone of tumor treatment，Standardized chemical treatment can improve the survival benefits of patients。

 

  Overview

 

  Eribici is a pillar variety

 

  According to the data disclosure of the "2015 Annual Report of China Tumor Registration"，In recent years，Tumor incidence of tumors in our country shows a continuous rise。From the perspective of the country，The first place in the onset of malignant tumors is lung cancer，Followed by gastric cancer、colorectal cancer、Liver cancer and esophageal cancer。The top 10 malignant tumors account for 76.39%，This phenomenon has attracted much attention。Under rigid demand，Promoting the localization of the anti -tumor drug market is already a big trend。

 

  Clinical clinical divide lung cancer into non -small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)，Where，Non -small cell lung cancer occupies most of lung cancer，instead of small cell lung cancer is subdivided into adenocarcinoma、Stake Sports BettingA variety of squamous carcinoma and large cell carcinoma。

 

  The treatment of lung cancer has surgical treatment、Radiation therapy、Chemical therapy and immunotherapy。Early diagnosis of lung cancer means that a considerable number of patients can cure and improve the survival rate，Comprehensive、Differential treatment can achieve better treatment effect。Current，Non -small cell lung cancer first -line chemotherapy schemes are card platinum or cisplatin and palag series drugs or Jeshabin。Small molecular targeted drugs have been released，Gefeitinib、Elotinib、Ekidinib and Permeusus are used as a second -line treatment plan，It can benefit from patients with lung cancer in middle -aged and elderly elderly。The current vitteric drug is already a pillar variety of lung cancer therapy drugs。

 

  New Moon Different Month of New Medicine of Lung Cancer

 

  According to the latest information, it shows，1997-March 2016，FDA in the United States approved a total of 128 anti -tumor drugs，From the perspective of classification，The main is chemotherapy and antibody drugs。

 

  In 2015, the total cost of China for cancer treatment reached 107 billion U.S. dollars，increased by 11.5%year -on -year。Data analysis from the anti -tumor drug market in 2015，Single clone antibody drugs account for 36.92%，Conventional chemotherapy drugs account for 27.84%，Small molecular targeted drugs account for 22.94%。

 

  As of June 2016，The FDA of the United States has approved a total of 72 targeting medicines，24 small molecular targeted perinomy drugs for treating lung cancer is 11，Occupy 46%in quantity。There are 6 small molecular targeted perinomy drugs that have been listed in China for lung cancer (see Figure 1)。

 

 

  Current，Small molecule targeted perinomy drugs that have not been introduced in our country are galotrifs approved by the FDA after 2013、、Tagrisso、Alecensa、XALKORI, etc.。

 

  Gradually in line with international standard

 

  Under rigid demand，In recent years, China's anti -tumor drug hospital drug market has shown a rapid growth trend。According to Mi Na.com data，In 2015, the lung cancer chemotherapy drug market in key cities in my country has reached 6509 billion yuan，increased by 5.61%year -on -year，Conservatively estimating China's lung cancer therapy market has reached 26 billion yuan in market scale。

 

 

  There are 34 chemotherapy drugs commonly used in domestic sample hospitals，The top ten positions are: paclitaxel、Dorixi、My stake betting appPeime Qucei、Forgio、Jesitabin、Eyzmei、Gefeitinib、Exitinib、Sorafeni、Elotinib。TOP 10 drugs for lung cancer occupying 78.75%of the lung cancer chemotherapy market。

 

  With the arrival of the precision medical era，Anti -tumor drug treatment shows personalized therapy、Differential Act、Target therapy、New characteristics of marketing for immunotherapy and combination therapy。Strong in national policy、In the environment of medical security in the year by year，Small molecular targeted drugs gradually enter people's vision。

 

  According to the Minenet HDM system data，In 2015, the amount of targeted drugs for lung cancer small molecules in public hospitals in China in my country reached 816 million yuan，increased by 12.02%year -on -year，and 2014 growth rate is as high as 47.76%。TOP 5 drugs are sorted by the amount of medication.、Exitinib、Sorafeni、Elotinib and Apatinib。Calculated according to industry insiders，The domestic market has exceeded 5 billion yuan in scale。

 

 

  At present, the drug variety of domestic sample hospitals for lung cancer has basically been in line with international standards，Peime Qucei、Elotinib、Exitinib、Gefeitinib、Sorafeni、Bevarzab、Reorganized rectification of human tumor necrosis factor (Tian Enfu)、Reorganized human vascular endothelial inhibitory (grace), etc., has all been used in clinical practice。

 

  Current，Under the influence of many factors such as medical insurance and patients can be used for medical expenditure，The main variety in the domestic and foreign lung cancer therapy market still has certain differences。Generally speaking，The international anti -tumor market is mainly targeting monoclonal anti -anti -anti -anti -targeting drugs; and in China，Pucco、Dorixi、Jesitabin、Table Roubi Xing、Card platinum、Cytotoxic drugs represented by isopic phosphide have always been the treatment plan for the key choice。

 

  In the past 10 years, lung cancer therapy has made a long way to move，The main discovery of lung cancer driving genes brought about this progress。Treatment of lung cancer，Targeted drugs also need to be combined with chemotherapy drugs。At present, it has initially formed a consensus on non -small cell lung cancer chemotherapy，Using cisplatin and Dadciti、Pucinol、Jesitabin、One or several of Changchun Ruibin，Select different combinations，Can achieve improvement、The purpose stake sports betting appof reducing the toxic response。

 

  variety

 

  Geffitinib: & ldquo; Leader & rdquo;

 

  Geffitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor。After the drug enters the body，Can improve conventional chemotherapy、Anti -tumor activity of radiotherapy and hormone therapy，Symptoms of improving metastatic non -small cell lung cancer，to improve the survival period of patients。

 

  Gefeitinib was developed and developed by Astrikan, UK，May 2003，FDA approves it to list in the United States，Commodity name is IRSSA (IRESS)，Become a clinical platinum and paclitaxel series compound preparation chemotherapy in advanced non -small cell lung cancer patients with third -line medication。Current，In the United States、Japan、Australia and China，Geffitinib is the main drug that is approved to treat advanced lung cancer or metastatic non -small cell lung cancer。

 

  The efficacy of Yerusa's curative effect on lung cancer abroad is controversial，It was once frustrated in Europe and the United States，Market performance ups and downs。Therefore，The sales performance of the 15 -year sales of Iraris has been listed in the world is only one -third of Roche Elotinib。

 

  February 2005，Astrikan's Geffitinib entered the Chinese market，The product is named & ldquo;。Geffitinib's EGFR mutations in patients with different ethnic lung cancer show certain activity，Its efficacy exceeds the commonly used first -line chemotherapy means。Research indication，Yerusa has a significant role in extending life for oriental people or never smoking people。At academic promotion、Under the complex situation when the price of drugs is too high，Its sales performance is in the trend of lingering。According to the Minenet HDM system data，2015 my country ’s key cities in China’ s public hospitals, Geffitinib, the amount of drugs for 253 million yuan，7.11%year -on -year。After the first batch of drug price negotiations from the National Health and Family Planning Commission，If you can enter the new medical insurance directory，can achieve the effect of getting the price at the price。

 

 

  Ekidinib: Flying accelerated, an average annual increase of 122%

 

  With the launch of the new generation of domestic nignic drugs，Small molecule targeted drug market share increases year by year。2015 domestic sample hospital market statistics show，Domestic Denibic Drug Market occupies 20%of the overall market for My stake betting appvine categories，Domestic small molecular targeted drugs have become the new highlights in the market。

 

  China's first small molecule targeted anti -tumor drug with completely independent intellectual property rights is an Exitinib in Zhejiang Beida Pharmaceutical，In the first approval in & ldquo;，Used for advanced non -small cell lung cancer，The product is named & ldquo; Camina & rdquo;。

 

  Ekntinib has China、The United States and International Patent，In chemical structure、Molecular action mechanism、efficacy and other aspects with Geffitinib、Elotinib is similar，but has better security，As a result, he has obtained a high evaluation of international clinical tumor experts，Gradually broke the situation of the imported drug monopoly market。

 

　　  The market size of Ernib is 896 million yuan.

 

 

  According to the market prospectus of Beida Pharmaceutical Company，During 3 years, Ekntinib's sales revenue has reached 2.058 billion yuan，and maintain a high growth rate for 4 consecutive years，The average annual growth rate is 122%，It is predicted that the drug will become the leader of the targeted drug market of lung cancer in 2016。